Key Insights

Highlights

Success Rate

84% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

10.7%

3 terminated out of 28 trials

Success Rate

84.2%

-2.3% vs benchmark

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

63%

10 of 16 completed with results

Key Signals

10 with results84% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (1)
P 1 (3)
P 2 (16)
P 3 (1)
P 4 (1)

Trial Status

Completed16
Recruiting4
Unknown4
Terminated3
Withdrawn1

Trial Success Rate

84.2%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (28)

Showing 20 of 20 trials
NCT03003572RecruitingPrimary

Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity

NCT06979531Phase 2RecruitingPrimary

Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

NCT06203457Phase 2CompletedPrimary

Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome

NCT06484855Phase 1CompletedPrimary

Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome

NCT05817669Phase 2CompletedPrimary

A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS)

NCT04981145Phase 4RecruitingPrimary

The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

NCT06432101Not ApplicableCompletedPrimary

Acupuncture Combined With Hydroxychloroquine

NCT04605978Phase 2CompletedPrimary

Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients

NCT04186871Phase 2Completed

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

NCT04684654Phase 1Terminated

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

NCT05087589Phase 2UnknownPrimary

Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome

NCT04078386Phase 2CompletedPrimary

A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome

NCT04975087UnknownPrimary

The Profile of Fatigue and Discomfort - Sicca Symptoms Inventory

NCT02149420Phase 2CompletedPrimary

PD of VAY736 in Patients With Primary Sjögren's Syndrome

NCT04858464UnknownPrimary

Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire

NCT03627065Phase 2CompletedPrimary

A Study of INCB050465 in Primary Sjögren's Syndrome

NCT02775916Phase 2CompletedPrimary

Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome

NCT02291029Phase 2CompletedPrimary

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

NCT02610543Phase 2TerminatedPrimary

UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome

NCT03040583RecruitingPrimary

The ASSESS National Multi-center Prospective Cohort

Scroll to load more

Research Network

Activity Timeline